JP6930969B2 - 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 - Google Patents

前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 Download PDF

Info

Publication number
JP6930969B2
JP6930969B2 JP2018520374A JP2018520374A JP6930969B2 JP 6930969 B2 JP6930969 B2 JP 6930969B2 JP 2018520374 A JP2018520374 A JP 2018520374A JP 2018520374 A JP2018520374 A JP 2018520374A JP 6930969 B2 JP6930969 B2 JP 6930969B2
Authority
JP
Japan
Prior art keywords
methylphenidate
gait
disease
pharmaceutical composition
participant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018520374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521127A (ja
JP2018521127A5 (enExample
Inventor
ローズマン ブルース
ローズマン ブルース
カプラン ギラ
カプラン ギラ
Original Assignee
ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー
ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/793,829 external-priority patent/US9307942B2/en
Priority claimed from US15/075,375 external-priority patent/US9682073B2/en
Application filed by ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー, ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー filed Critical ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー
Publication of JP2018521127A publication Critical patent/JP2018521127A/ja
Publication of JP2018521127A5 publication Critical patent/JP2018521127A5/ja
Priority to JP2021018221A priority Critical patent/JP7350794B2/ja
Application granted granted Critical
Publication of JP6930969B2 publication Critical patent/JP6930969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018520374A 2015-07-08 2016-06-14 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 Active JP6930969B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021018221A JP7350794B2 (ja) 2015-07-08 2021-02-08 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14/793,829 US9307942B2 (en) 2011-05-19 2015-07-08 Treatment for cerebral palsy gait impairment
US14/793,829 2015-07-08
US14/881,516 2015-10-13
US14/881,516 US9333198B2 (en) 2011-05-19 2015-10-13 Treatment for cerebral palsy gait impairment
US14/971,325 2015-12-16
US14/971,325 US9408838B2 (en) 2011-05-19 2015-12-16 Treatment for cerebral palsy gait impairment
US15/075,375 2016-03-21
US15/075,375 US9682073B2 (en) 2011-05-19 2016-03-21 Pre-frontal cortex processing disorder gait and limb impairments treatment
PCT/US2016/037367 WO2017007577A1 (en) 2015-07-08 2016-06-14 Pre-frontal cortex processing disorder, gait and limb impairment treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021018221A Division JP7350794B2 (ja) 2015-07-08 2021-02-08 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療

Publications (3)

Publication Number Publication Date
JP2018521127A JP2018521127A (ja) 2018-08-02
JP2018521127A5 JP2018521127A5 (enExample) 2019-06-20
JP6930969B2 true JP6930969B2 (ja) 2021-09-01

Family

ID=57686013

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520374A Active JP6930969B2 (ja) 2015-07-08 2016-06-14 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
JP2021018221A Active JP7350794B2 (ja) 2015-07-08 2021-02-08 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021018221A Active JP7350794B2 (ja) 2015-07-08 2021-02-08 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療

Country Status (6)

Country Link
EP (1) EP3319603B1 (enExample)
JP (2) JP6930969B2 (enExample)
CN (1) CN108025003B (enExample)
CA (1) CA2991529C (enExample)
MX (1) MX2017016910A (enExample)
WO (1) WO2017007577A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017007577A1 (en) * 2015-07-08 2017-01-12 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2157880A (en) 1937-01-22 1939-05-09 Electrical Res Prod Inc Recording system
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US4145083A (en) 1977-06-17 1979-03-20 Urban Frank K Therapeutic chair for cerebral palsy child
US4844075A (en) 1984-01-09 1989-07-04 Pain Suppression Labs, Inc. Transcranial stimulation for the treatment of cerebral palsy
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6121261A (en) 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
RU2185106C1 (ru) 2001-07-12 2002-07-20 Свадовский Александр Игоревич Способ нейрохирургического лечения детского церебрального паралича
US8952895B2 (en) * 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
JP4943845B2 (ja) * 2003-09-17 2012-05-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ サリドマイド類似体
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
US20050182097A1 (en) 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
AU2006216646B2 (en) * 2005-02-23 2012-05-31 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications
EP2032987B1 (en) * 2006-05-22 2016-02-24 The Board of Trustees of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
EP1985276A1 (en) 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
US20110270345A1 (en) 2007-08-11 2011-11-03 Johns Hopkins University Focal noninvasive stimulation of the sensory cortex of a subject with cerebral palsy
CN102170874A (zh) * 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
US20120245201A1 (en) * 2009-07-23 2012-09-27 Markowitz John S Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions
EP2521546A4 (en) 2010-01-07 2013-06-26 Vivus Inc TREATMENT OF THE OBSTRUCTIVE SLEEP APNEO SYNDROME COMBINED WITH ANTIBODY ANTIBODY AND AN ADDITIONAL ACTIVE SUBSTANCE
CN102792513A (zh) * 2010-03-01 2012-11-21 波士顿电力公司 具有平均温度及热点回授之热感测器装置
EP2544688B1 (en) * 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
US9682073B2 (en) * 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
KR20130016127A (ko) * 2011-08-04 2013-02-14 의료법인 성광의료재단 외상성 뇌손상의 치료
AU2012348505B2 (en) * 2011-12-08 2016-10-06 APOS Medical Assets Ltd Device and methods for treating neurological disorders
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
US9305307B2 (en) * 2013-07-15 2016-04-05 Google Inc. Selecting content associated with a collection of entities
US20150133667A1 (en) * 2013-11-08 2015-05-14 Noramco, Inc. Process for the preparation of methylphenidate and pharmaceutical salts thereof
WO2017007577A1 (en) 2015-07-08 2017-01-12 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment

Also Published As

Publication number Publication date
JP7350794B2 (ja) 2023-09-26
JP2018521127A (ja) 2018-08-02
EP3319603A1 (en) 2018-05-16
EP3319603B1 (en) 2021-11-17
EP3319603A4 (en) 2019-03-13
JP2021088571A (ja) 2021-06-10
WO2017007577A1 (en) 2017-01-12
CN108025003B (zh) 2021-07-13
CN108025003A (zh) 2018-05-11
MX2017016910A (es) 2018-08-15
CA2991529C (en) 2021-01-05
CA2991529A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
US9333198B2 (en) Treatment for cerebral palsy gait impairment
Kawahira et al. Addition of intensive repetition of facilitation exercise to multidisciplinary rehabilitation promotes motor functional recovery of the hemiplegic lower limb.
EP2667869A1 (en) Use of potassium channel blockers to treat cerebral palsy
US9682073B2 (en) Pre-frontal cortex processing disorder gait and limb impairments treatment
JP7350794B2 (ja) 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
US11102953B2 (en) Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
Torok Physical therapy rehabilitation in a patient with Guillain-Barré syndrome with acute respiratory failure: a case report
RU2465023C1 (ru) Способ лечения детей с двигательными нарушениями
IONICĂ et al. Evaluation of physiotherapy effects using specific tests in Duchenne muscular dystrophy–a case study
Guru et al. The rehabilitation interventions and adaptive technologies used for treating patients with cerebral palsy
Lockley et al. Physical management of spasticity
JP2019517516A (ja) Ｓｍａの新規な処置
Shukla et al. Physical Therapy in a Patient with Viral-encephalitis Hemi-Paresis: A Case Report
Deibert et al. Motor restoration and spasticity management after stroke
Aljasir et al. Physical Therapy Rehabilitation for a Patient with Complex Regional Pain Syndrome: A
Özçelep et al. Rehabilitation for Mitochondrial Membrane Protein-Related Neurodegeneration: A Case Study
Aybar et al. Overview of Cerebral Palsy and Non-Surgical Treatment Methods
Gelber Management of spasticity
Marsden et al. Hereditary spastic paraparesis and other hereditary myelopathies
Sinno et al. Enhancing Childhood Development in Children with Cerebral Palsy and Other Disorders
Amin et al. Stroke Rehab
HK1262519A1 (en) New treatment of sma
¹Paris Iakovidis et al. IJPHY
WO2017111052A1 (ja) 自己免疫疾患治療剤
Parfenov Muscle hypertonicity after stroke treatment. What is spasticity and how to deal with muscle spasticity. How to treat spasticity using different methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210208

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20210208

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210406

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210812

R150 Certificate of patent or registration of utility model

Ref document number: 6930969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250